Predicted Trait | |
Reported Trait | Prostate carcinoma |
Mapped Trait(s) | prostate carcinoma (EFO_0001663) |
Score Construction | |
PGS Name | SBayesR |
Development Method | |
Name | SBayesR |
Parameters | SBayesR adjusts GWAS SNP effect estimates using a Bayesian approach. This method assumes that standardised SNP effects are drawn from a mixture of four distributions, allowing for greater flexibility by varying the proportion of SNPs within each distribution. With the default settings and sparse LD matrix, the scaling factor (𝛾) for the variance of each mixture component is set to 0, 0.01, 0.1, and 1, respectively. SBayesR estimates the fraction of causal SNPs directly from the GWAS summary statistics, eliminating the need for a tuning sample. |
Variants | |
Original Genome Build | GRCh37 |
Number of Variants | 904,103 |
Effect Weight Type | beta |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000741 |
Citation (link to publication) | Tanha HM et al. HGG Adv (2025) |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
GWAS Catalog: GCST011049 Europe PMC: 33398198 |
177,526 individuals | European | NR |
GWAS Catalog: GCST011049 Europe PMC: 33398198 |
21,354 individuals | African American or Afro-Caribbean,African unspecified | NR |
GWAS Catalog: GCST011049 Europe PMC: 33398198 |
27,420 individuals | East Asian | NR |
GWAS Catalog: GCST011049 Europe PMC: 33398198 |
7,953 individuals | Hispanic or Latin American | NR |
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM022673 | PSS012056| European Ancestry| 184,010 individuals |
PGP000741 | Tanha HM et al. HGG Adv (2025) |
Reported Trait: 5-year incident prostate cancer | — | AUROC: 0.694 [0.685, 0.703] | — | - | — |
PPM022678 | PSS012055| African Ancestry| 3,193 individuals |
PGP000741 | Tanha HM et al. HGG Adv (2025) |
Reported Trait: 5-year incident prostate cancer | — | AUROC: 0.553 [0.495, 0.61] | — | - | — |
PPM022683 | PSS012057| South Asian Ancestry| 5,097 individuals |
PGP000741 | Tanha HM et al. HGG Adv (2025) |
Reported Trait: 5-year incident prostate cancer | — | AUROC: 0.699 [0.615, 0.784] | — | - | — |
PPM022688 | PSS012054| European Ancestry| 6,791 individuals |
PGP000741 | Tanha HM et al. HGG Adv (2025) |
Reported Trait: 5-year incident prostate cancer | — | AUROC: 0.699 [0.668, 0.73] | — | - | — |
PPM022703 | PSS012057| South Asian Ancestry| 5,097 individuals |
PGP000741 | Tanha HM et al. HGG Adv (2025) |
Reported Trait: 5-year incident prostate cancer | — | AUROC: 0.836 [0.78, 0.893] | — | Age-specific absolute risk adjusted by PGS relative risk | — |
PPM022708 | PSS012055| African Ancestry| 3,193 individuals |
PGP000741 | Tanha HM et al. HGG Adv (2025) |
Reported Trait: 5-year incident prostate cancer | — | AUROC: 0.793 [0.755, 0.831] | — | Age-specific absolute risk adjusted by PGS relative risk | — |
PPM022713 | PSS012054| European Ancestry| 6,791 individuals |
PGP000741 | Tanha HM et al. HGG Adv (2025) |
Reported Trait: 5-year incident prostate cancer | — | AUROC: 0.736 [0.709, 0.763] | — | Age-specific absolute risk adjusted by PGS relative risk | — |
PPM022718 | PSS012053| European Ancestry| 1,809 individuals |
PGP000741 | Tanha HM et al. HGG Adv (2025) |
Reported Trait: 5-year incident prostate cancer | — | AUROC: 0.713 [0.683, 0.742] | — | Age-specific absolute risk adjusted by PGS relative risk | — |
PPM022693 | PSS012053| European Ancestry| 1,809 individuals |
PGP000741 | Tanha HM et al. HGG Adv (2025) |
Reported Trait: 5-year incident prostate cancer | — | AUROC: 0.702 [0.672, 0.732] | — | - | — |
PPM022698 | PSS012056| European Ancestry| 184,010 individuals |
PGP000741 | Tanha HM et al. HGG Adv (2025) |
Reported Trait: 5-year incident prostate cancer | — | AUROC: 0.787 [0.78, 0.794] | — | Age-specific absolute risk adjusted by PGS relative risk | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS012053 | Linked cancer registry records were used to identify participants diagnosed with incident malignant neoplasm of the prostate (ICD-10 code: C61; ICD-9 code: 185) within five years of prediction baseline. | — | [ ,
100.0 % Male samples |
European | PC1-PC4 values ±3s.d. from the 1000G European cluster | MCCS | MCCS had a case/sub-cohort design, leading to a higher proportion of cases | |
PSS012054 | Linked cancer registry records were used to identify participants diagnosed with incident malignant neoplasm of the prostate (ICD-10 code: C61; ICD-9 code: 185) within five years of prediction baseline. | — | [ ,
100.0 % Male samples |
European | PC1-PC4 values ±3s.d. from the 1000G European cluster | QSKIN | — | |
PSS012055 | Linked cancer registry records were used to identify participants diagnosed with incident malignant neoplasm of the prostate (ICD-10 code: C61; ICD-9 code: 185) within five years of prediction baseline. | — | [ ,
100.0 % Male samples |
African American or Afro-Caribbean | AFR individuals were identified by PC1-PC4 from 1000G and k-means clustering. | UKB | — | |
PSS012056 | Linked cancer registry records were used to identify participants diagnosed with incident malignant neoplasm of the prostate (ICD-10 code: C61; ICD-9 code: 185) within five years of prediction baseline. | — | [ ,
100.0 % Male samples |
European | EUR individuals were identified by PC1-PC4 from 1000G and k-means clustering. | UKB | — | |
PSS012057 | Linked cancer registry records were used to identify participants diagnosed with incident malignant neoplasm of the prostate (ICD-10 code: C61; ICD-9 code: 185) within five years of prediction baseline. | — | [ ,
100.0 % Male samples |
South Asian | SAS individuals were identified by PC1-PC4 from 1000G and k-means clustering. | UKB | — |